PolyPid presents PD01B development plans for diabetic foot infections

PUBT · 4d ago
PolyPid presents PD01B development plans for diabetic foot infections
  • PolyPid expects D-PLEX100's US launch in early 2027, subject to FDA approval; the target decision date is November 28, 2026.
  • The Azurity Pharma deal includes more than $320 million in development and sales milestones, with $30 million already paid.
  • Tiered royalties range from mid-teens to mid-20s percentages of net sales; Azurity will fund clinical development for label expansion.
  • European commercial rights to D-PLEX100 have been regained; its marketing application is under review, with potential partnership discussions active.
  • Investigational PD01B targets moderate to severe diabetic foot infections; first-in-human testing is expected in the second half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PolyPid Ltd. published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.